⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
prnewswire.com
REGN
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
REGN
$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law
globenewswire.com
REGN
Pomerantz LLP Advises Shareholders of Class Action Filing Against Regeneron Pharmaceuticals, Inc. – REGN
accessnewswire.com
REGN
Investor Alert: Deadline Approaching to Join Regeneron Pharmaceuticals, Inc. (REGN) Class Action – Contact Levi & Korsinsky
accessnewswire.com
REGN
Recover Investment Losses: Class Action Initiated Against Regeneron Pharmaceuticals, Inc. (REGN)
accessnewswire.com
REGN
Regeneron Pharmaceuticals, Inc. (REGN) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 14, 2026 Deadline
accessnewswire.com
REGN
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. (REGN) Shareholders of Class Action Lawsuit and September 14, 2026 Deadline
accessnewswire.com
REGN
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
prnewswire.com
REGN
MRK
ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
prnewswire.com
PFE
MRK
LLY
AMGN
BMY
NVS
GILD
AZN
REGN
SNY
TEVA
IMUX